InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) to Present at NIBA 153rd Investment Conference
October 6, 2026
NanoViricides, Inc. (NYSE American: NNVC) announced that it will present Oct. 7, 2026, at NIBA 153rd Investment Conference in Fort Lauderdale, Florida. The clinical-stage company is developing nanomedicines for antiviral therapy, led by NV-387, a broad-spectrum antiviral currently in separate Phase 2 clinical trials in the Democratic Republic of Congo for Ebola Bundibugyo virus disease […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Provides Update on Phase II Ebola Trial of NV-387 Oral Gummies
October 5, 2026
NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing antiviral drugs, provided additional details on its Phase II clinical trial of NV-387 Oral Gummies for treatment of the current Bundibugyo Ebolavirus “BDBV” outbreak and other Ebola viruses in the Democratic Republic of Congo. The company said the trial is proceeding as designed, with enrollment in […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Reports Fiscal 2026 Results, Advances NV-387 Phase II Trials
September 29, 2026
NanoViricides, Inc. (NYSE American: NNVC) reported results for its fiscal year ended June 30, 2026, highlighting regulatory and clinical progress for broad-spectrum antiviral candidate NV-387. The company received regulatory approval in the Democratic Republic of Congo for Phase II trials evaluating NV-387 Oral Gummies for the treatment of Mpox and Ebola, with both trials beginning […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Begins Patient Enrollment and Dosing in Phase II NV-387 Ebola Trial
September 28, 2026
NanoViricides, Inc. (NYSE American: NNVC) announced that its Phase II clinical trial evaluating NV-387 Oral Gummies as a treatment for Bundibugyo Ebolavirus and other Ebola viruses has begun enrolling and dosing patients at an Ebola Treatment Center in the Ituri province of the Democratic Republic of Congo (“DRC”). The Phase IIA portion began enrollment and […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Phase II Ebola Trial of NV-387 Oral Gummies Set to Begin Next Week in DRC
September 15, 2026
NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing antiviral drugs, announced that its Phase II clinical trial evaluating NV-387 Oral Gummies as a treatment for Bundibugyo Ebolavirus and other Ebola viruses is scheduled to begin next week at an Ebola Treatment Center in the Ituri province of the Democratic Republic of Congo (“DRC”). The […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Registers Phase II Ebola Trial for NV-387 Oral Gummies
September 8, 2026
NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage developer of antiviral drugs, announced that its phase II clinical trial evaluating NV-387 Oral Gummies as a treatment for Bundibugyo ebolavirus and other Ebola viruses in the Democratic Republic of Congo (“DRC”) has been registered in the Pan African Clinical Trials Registry under identification number PACTR202608748555077. The company […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Advances NV-387 Measles Treatment Program Toward Phase II Trial
August 31, 2026
NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage developer of broad-spectrum antivirals based on host-mimetic nanomedicine technology, provided an update on its NV-387 measles treatment program as measles cases continue to rise in the U.S. and globally. The company is developing a Phase II clinical trial protocol to evaluate NV-387 as a treatment for measles and intends […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Expects Phase II Ebola Trial of NV-387 Oral Gummies to Begin Soon in DRC
August 18, 2026
NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing antiviral drugs, announced that a Phase II clinical trial of NV-387 Oral Gummies for treatment of the current Bundibugyo Ebolavirus and other Ebola viruses is expected to begin soon in the Democratic Republic of Congo (“DRC”). The company has received regulatory approval from local agency ACOREP […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Receives Regulatory Approval for Phase II Ebola Trial of NV-387 Oral Gummies
August 10, 2026
NanoViricides, Inc. (NYSE American: NNVC) announced that it has received regulatory approval from the local regulatory agency “ACOREP” in the Democratic Republic of Congo (“DRC”) to begin a Phase II clinical trial of NV-387 Oral Gummies as a treatment for the current Bundibugyo ebolavirus outbreak and other Ebola viruses. The company has retained Om Sai Clinical Research Private […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Awaits Regulatory Decision on Ebola Trial for NV-387 Oral Gummies
July 28, 2026
NanoViricides, Inc. (NYSE American: NNVC) announced it is awaiting regulatory approval to begin a Phase II clinical trial of its NV-387 Oral Gummies for the treatment of Bundibugyo ebolavirus in the Democratic Republic of the Congo after submitting an application to the local regulatory agency. The company said it has secured financing to support the […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Announces Approximately $3.8 Million Registered Direct Offering
July 24, 2026
NanoViricides, Inc. (NYSE American: NNVC) announced it entered into a securities purchase agreement with a single fundamental institutional investor for the purchase and sale of 2,516,339 common shares, or pre-funded warrants in lieu thereof, together with warrants to purchase an equal number of common shares. The registered direct offering is expected to generate approximately $3.8 […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Seeks Approval to Launch Phase II Ebola Trial in DRC
July 22, 2026
NanoViricides, Inc. (NYSE American: NNVC) announced it has applied to the Democratic Republic of Congo’s regulatory agency for approval to begin a Phase II clinical trial evaluating its NV-387 Oral Gummies as a treatment for the current Bundibugyo ebolavirus outbreak. The company said it has retained Om Sai Clinical Research Private Limited as the contract research organization for […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Receives Ethics Approval for Phase II Ebola Trial in DRC
July 13, 2026
NanoViricides, Inc. (NYSE American: NNVC) announced it has received National Ethics Committee approval in the Democratic Republic of the Congo (“DRC”) for a Phase II clinical trial evaluating its NV-387 oral gummies as a treatment for the current Bundibugyo ebolavirus outbreak. The company is preparing to submit a Clinical Trial Application to the DRC regulatory agency, ACOREP, and […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Coverage Initiated With Outperform Rating, $6 Price Target
July 8, 2026
NanoViricides, Inc. (NYSE American: NNVC) announced that independent analyst Robert LeBoyer of Noble Capital Markets has initiated research coverage of the clinical-stage antiviral drug developer with an “Outperform” rating and a $6.00 price target. The report reviews the company’s lead programs, including its broad-spectrum antiviral candidate NV-387, along with longer-term development initiatives. NanoViricides noted that […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Advances NV-387 Toward Phase II Trial for Bundibugyo Ebola in DRC
July 6, 2026
NanoViricides, Inc. (NYSE American: NNVC) announced continued progress advancing its broad-spectrum antiviral drug candidate NV-387 toward a Phase II clinical trial evaluating its oral gummies formulation as a treatment for the current Bundibugyo ebolavirus outbreak in the Democratic Republic of the Congo (“DRC”). The company said its proposed clinical trial has been approved by the […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Ships NV-387 Drug Supply to DRC for Phase II MPox Trial
June 22, 2026
NanoViricides, Inc. (NYSE American: NNVC) announced that it has shipped NV-387 Oral Gummies to the Democratic Republic of Congo in preparation for a Phase II clinical trial evaluating the drug as a treatment for MPox. The company said site preparations are being conducted by its contract research organization, Om Sai Clinical Research Pvt. Ltd., and local partners, […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Receives DRC Approval to Advance Proposed Phase II Ebola Trial
June 15, 2026
NanoViricides, Inc. (NYSE American: NNVC) announced that the Pillar Committee in Charge in the Democratic Republic of Congo has approved the company’s proposal to conduct a Phase II clinical trial evaluating NV-387 Oral Gummies as a treatment for the current Bundibugyo ebolavirus outbreak. The company said NV-387 is a broad-spectrum antiviral designed to target host-cell […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights NV-387 as Potential Candidate for Bundibugyo Ebola Outbreak
May 26, 2026
NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, said its broad-spectrum antiviral candidate NV-387 warrants evaluation as a potential treatment option for the rapidly expanding Bundibugyo strain Ebola outbreak in Africa, citing the absence of approved vaccines or therapies specifically targeting the virus strain. The company said NV-387’s host-targeted antiviral mechanism and oral […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Closes $2 Million Registered Direct Offering
May 19, 2026
NanoViricides, Inc. (NYSE American: NNVC) announced the closing of its previously announced registered direct offering with a single institutional investor, consisting of 1,333,334 shares of common stock, or pre-funded warrants in lieu thereof, along with accompanying warrants to purchase 1,333,334 additional common shares. The offering was priced at $1.50 per share and accompanying warrant, generating aggregate gross proceeds of approximately $2 million before fees […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights Broad-Spectrum Antiviral Candidate Amid Ebola Outbreak
May 18, 2026
NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, highlighted the potential of its broad-spectrum antiviral candidate NV-387 in response to the ongoing Bundibugyo Ebola outbreak in the Democratic Republic of Congo and Uganda, stating the oral drug candidate could offer a differentiated approach if proven effective against the virus strain. The company emphasized […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Prices $2 Million Registered Direct Offering
May 15, 2026
NanoViricides, Inc. (NYSE American: NNVC) announced a securities purchase agreement with a single institutional investor for a registered direct offering expected to generate approximately $2 million in gross proceeds through the sale of 1,333,334 common shares, or pre-funded warrants in lieu thereof, along with accompanying warrants to purchase an equal number of common shares. The […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Advances NV-387 Development Across Multiple Viral Disease Targets
May 15, 2026
NanoViricides, Inc. (NYSE American: NNVC) announced the filing of its quarterly report for the period ended March 31, 2026, highlighting continued advancement of its broad-spectrum antiviral candidate NV-387 toward Phase II clinical development for MPox in the Democratic Republic of Congo, where regulatory approval for the trial has already been obtained. The company also outlined progress in its […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights Broad-Spectrum Antiviral Candidate Following Andes Hantavirus Incident
May 11, 2026
NanoViricides, Inc. (NYSE American: NNVC) highlighted the potential need for broad-spectrum antiviral treatments following the recent Andes hantavirus incident aboard a cruise ship, pointing to its clinical-stage antiviral candidate NV-387 as a potential therapeutic platform for emerging viral threats. The company said NV-387 has completed a Phase I safety and tolerability trial in healthy volunteers […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) to Participate in D. Boral Capital Global Conference
May 7, 2026
NanoViricides, Inc. (NYSE American: NNVC) announced its participation in the D. Boral Capital Global Conference on May 7, 2026, at The Plaza Hotel in New York City, where Anil R. Diwan, Ph.D., president and executive chairman, will host one-on-one meetings with investors and interested parties from 9:45 a.m. to 2:45 p.m. ET. To view the […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Receives Orphan Drug Designation for NV-387
May 4, 2026
NanoViricides, Inc. (NYSE American: NNVC) announced that its clinical-stage antiviral drug NV-387 has been granted Orphan Drug Designation by the U.S. FDA for the treatment of measles, providing potential incentives including tax credits, fee exemptions and market exclusivity. The company said the designation supports regulatory advancement of NV-387, a broad-spectrum antiviral candidate that has demonstrated […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights NV-387 as Potential Measles Treatment
April 21, 2026
NanoViricides, Inc. (NYSE American: NNVC) announced that its antiviral drug candidate NV-387 may address the growing global measles outbreak, citing recent case surges including more than 18,000 suspected infections in Bangladesh and rising cases in the United States. The company stated that NV-387 has demonstrated safety in Phase I clinical trials and efficacy in animal models, […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Files for Rare Pediatric Disease Designation for Measles Drug Candidate
April 7, 2026
NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing broad-spectrum antivirals, announced it has filed an application with the U.S. FDA for Rare Pediatric Disease Drug designation for NV-387 as a treatment for measles. The application, which follows a previously submitted orphan drug designation filing, could make the company eligible for a Priority Review Voucher […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) to Initiate Phase II MPox Trial in DRC
April 1, 2026
NanoViricides, Inc. (NYSE American: NNVC) announced that a Phase II clinical trial of its antiviral candidate NV-387 for the treatment of MPox is expected to begin soon in the Democratic Republic of Congo, with site preparation and staff training scheduled for early April 2026. The study, already approved by the DRC regulatory agency, will evaluate […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) to Present at NIBA Investment Conference As NV-387 Oral Gummies Drug Supply Completed
March 11, 2026
NanoViricides, Inc. (NYSE American: NNVC) announced that it will present at NIBA’s 152nd Investment Conference in Fort Lauderdale on March 12, where President and Executive Chairman Anil R. Diwan will outline progress on the company’s broad-spectrum antiviral platform. The company also reported that manufacturing of its NV-387 Oral Gummies drug product has been completed in […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Files Orphan Drug Designation Application for NV-387 in MPox
February 12, 2026
NanoViricides, Inc. (NYSE American: NNVC) announced it has filed an application for Orphan Drug Designation for NV-387 as a treatment for MPox with the U.S. FDA Office of Orphan Products Development. If granted, the designation would provide incentives including tax credits for qualified clinical trials, exemption from certain user fees and potential seven years of […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Files Orphan Drug Designation Application for NV-387 as Measles Treatment
February 10, 2026
NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral developer, announced that it has filed an application with the U.S. Food and Drug Administration Office of Orphan Products Development for Orphan Drug Designation for NV-387 as a treatment for measles. If granted, the designation would make the Company eligible for incentives including tax credits for qualified clinical […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights Mission Matters Podcast Interview With President Anil Diwan
February 2, 2026
NanoViricides, Inc. (NYSE American: NNVC) announced that President Dr. Anil R. Diwan was interviewed on the Mission Matters Podcast, where he discussed the company’s mission to revolutionize antiviral treatment through its nanoviricide platform and highlighted progress of lead drug candidate NV-387. During the interview, Dr. Diwan explained how nanoviricides are designed to prevent viral escape, […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights Need for Broad-Spectrum Antivirals Amid Severe Influenza Season
January 13, 2026
NanoViricides, Inc. (NYSE American: NNVC) said the current severe influenza wave underscores the urgent need for broad-spectrum antiviral therapies capable of addressing influenza, RSV, coronaviruses and other respiratory viruses, citing limitations of seasonal vaccines and existing antivirals that face timing constraints and resistance risks. The Company highlighted its Phase II-stage drug candidate NV-387, a broad-spectrum […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Signs Master Services Agreement With Only Orphans Cote for NV-387 Orphan Drug Strategy
December 1, 2025
NanoViricides, Inc. (NYSE American: NNVC), a clinical stage global pioneer in broad-spectrum antivirals based on host-mimetic nanomedicine, signed a Master Services Agreement with regulatory consultant Only Orphans Cote, founded by Dr. Timothy Cote. OOC will help develop the Company’s orphan drug strategy for NV-387 and prepare and prosecute related orphan drug designation applications at the […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Files Quarterly Report Highlighting Broad-Spectrum Antiviral Candidate NV-387
November 17, 2025
NanoViricides, Inc. (NYSE American: NNVC) filed its Form 10-Q for the quarter ended Sept. 30, 2025, and detailed progress on NV-387, a first-in-class broad-spectrum antiviral designed to resist viral escape by mimicking conserved sulfated proteoglycan receptors used by more than 90% of viruses. The Company noted that NV-387’s mechanism may address major unmet needs across […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Closes $6 Million Registered Direct Offering With Concurrent Private Placement of Warrants
November 13, 2025
NanoViricides, Inc. (NYSE American: NNVC), closed its previously announced $6 million registered direct offering of 3,571,429 shares of common stock at $1.68 per share with a single healthcare institutional investor, alongside a concurrent private placement of Series A and Series B warrants for an equal number of shares with exercise prices of $1.75 and $2.00, […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Announces $6 Million Registered Direct Offering with Concurrent Private Placement of Warrants
November 11, 2025
NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing broad-spectrum antiviral nanomedicines, today announced it has entered into a securities purchase agreement with a single healthcare institutional investor for the purchase of 3,571,429 shares of common stock (or equivalents) at $1.68 per share in a registered direct offering, for expected gross proceeds of approximately $6 […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Receives Regulatory Approval to Begin Phase II Trial of NV-387 for Treatment of MPox in the DRC
November 10, 2025
NanoViricides, Inc. (NYSE American: NNVC) announced that the Democratic Republic of Congo’s regulatory agency, ACOREP, has approved the start of a Phase II clinical trial evaluating NV-387 for the treatment of MPox caused by hMPXV infection. The trial will assess safety and effectiveness, pending final document submissions. “This is an important milestone in regulatory development […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Announces Date and Location of 2025 Annual Shareholders Meeting
November 5, 2025
NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing broad-spectrum antiviral drugs designed to prevent viral escape, announced that its Annual Shareholders Meeting will be held at 10 a.m. on Saturday, Nov. 8, 2025, at the Hampton Inn & Suites in Stamford, Connecticut. To view the full press release, visit https://ibn.fm/7IcXQ ABOUT NANOVIRICIDES NanoViricides, Inc. […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) to Present at Spartan Capital Investor Conference 2025
November 3, 2025
NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage developer of broad-spectrum antiviral drugs designed to prevent viral escape, announced it will present today, Nov. 3, 2025, at 9:45 a.m. ET at the Spartan Capital Investor Conference in New York City. To view the full press release, visit https://ibn.fm/cnCIM About NanoViricides NanoViricides, Inc. (the “Company”) (www.nanoviricides.com) is […]